Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adaptimmune Therapeutics Plc

ADAP
Current price
0.26 USD +0.011 USD (+4.50%)
Last closed 0.26 USD
ISIN US00653A1079
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 61 272 660 USD
Yield for 12 month -75.71 %
1Y
3Y
5Y
10Y
15Y
ADAP
21.11.2021 - 28.11.2021

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.71 USD

P/E ratio

Dividend Yield

Current Year

+178 032 000 USD

Last Year

+60 281 000 USD

Current Quarter

+3 222 000 USD

Last Quarter

+40 901 000 USD

Current Year

+177 962 000 USD

Last Year

+50 423 941 USD

Current Quarter

+3 222 000 USD

Last Quarter

+40 901 000 USD

Key Figures ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -41 184 000 USD
Operating Margin TTM -2 002.30 %
Price to Earnings
Return On Assets TTM -12.39 %
PEG Ratio 0.11
Return On Equity TTM -275.74 %
Wall Street Target Price 1.71 USD
Revenue TTM 178 032 000 USD
Book Value 0.046 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1 294.80 %
Dividend Yield
Gross Profit TTM 28 902 000 USD
Earnings per share -0.30 USD
Diluted Eps TTM -0.30 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin -39.78 %

Dividend Analytics ADAP

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.64
Price Sales TTM 0.34
Enterprise Value EBITDA -1.71
Price Book MRQ 5.17

Financials ADAP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADAP

For 52 weeks

0.20 USD 1.48 USD
50 Day MA 0.41 USD
Shares Short Prior Month 5 642 793
200 Day MA 0.76 USD
Short Ratio 2.26
Shares Short 5 454 233
Short Percent 3.17 %